Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 1.00e-2 | 2.76e-2 |
Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 1.00e-3 | 9.87e-3 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 5.00e-2 | 1.30e-3 |
Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 5.00e-2 | 1.83e-2 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-5 | 3.24e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-3 | 1.38e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 4.32e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 1.37e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 1.02e-3 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-4 | 3.20e-3 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 5.00e-2 | 1.38e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 1.96e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-2 | 3.45e-3 |
Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 1.00e-3 | 3.38e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 1.19e-2 |
Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-3 | 2.59e-2 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 5.00e-2 | 3.20e-4 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 2.26e-3 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 3.75e-4 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 6.91e-4 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 3.24e-5 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 5.00e-2 | 3.07e-2 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-3 | 4.05e-2 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 4.61e-2 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-2 | 4.46e-2 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 6.32e-3 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 4.31e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 5.00e-2 | 3.94e-2 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-2 | 1.64e-2 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.06e-2 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.24e-2 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 8.09e-3 |
Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.02e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.22e-3 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 5.40e-3 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 4.16e-2 |
BMI Age Stratified | BMI Men Age Under 50 | MTC | Winkler | 2015 | NA | 51625 | 1.00e-2 | 2.34e-2 |
BMI Physical Activity Interaction | BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.77e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.66e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.45e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.17e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 6.08e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.65e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.94e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 1.00e-5 | 1.58e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 15 to 30 | MTC | Medina-Gomez | 2018 | NA | 4180 | 1.00e-2 | 4.02e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 1.89e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 4.12e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 5.00e-2 | 6.01e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 1.00e-2 | 2.50e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 5.10e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 2.79e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-3 | 4.25e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-4 | 1.15e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-5 | 4.46e-2 |
Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 1.00e-2 | 4.65e-2 |
Diarrhoeal Disease | Diarrhea Age 1 | MTC | Bustamante | 2016 | 2693 | 3065 | 5.00e-2 | 1.52e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 5.53e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 5.00e-2 | 2.99e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 1.00e-2 | 4.66e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 3.37e-2 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.28e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 5.00e-2 | 4.37e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 2.59e-4 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 8.67e-5 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 2.81e-3 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 3.03e-4 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 1.03e-5 |
Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 1.13e-2 |
Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 1.00e-3 | 5.87e-3 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 1.00e-2 | 4.21e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 1.72e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 2.72e-3 |
Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-3 | 2.01e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 5.00e-2 | 1.62e-2 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 5.00e-2 | 3.24e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.04e-2 |
Statin Efficacy | Delta HDL With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 5.98e-3 |
Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.45e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 5.00e-2 | 4.28e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 2.91e-2 |
Waist Format 1 | Hip Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 4.21e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.98e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 2.27e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.24e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.57e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 1.53e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 8.21e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 3.22e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 3.24e-2 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 7.32e-3 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 2.06e-3 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 1.32e-4 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 1.11e-2 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 1.53e-2 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 4.56e-3 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 1.64e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 4.83e-2 |
K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 3.52e-2 |
Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-2 | 6.68e-3 |
Sleep | Sleep duration | ETC | Dashti | 2019 | NA | 446118 | 5.00e-2 | 4.98e-2 |
BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 5.00e-2 | 4.65e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 5.00e-2 | 3.68e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-3 | 2.75e-2 |
Neuroticism | Neuroticism | ETC | Baselmans | 2019 | NA | 523783 | 1.00e-4 | 1.04e-2 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 1.85e-3 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 1.12e-2 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.54e-2 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.10e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 3.47e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 4.92e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 7.13e-4 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 9.34e-3 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 1.00e-2 | 2.62e-3 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 1.00e-3 | 2.42e-3 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-5 | 2.85e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-5 | 2.73e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 2.64e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 4.89e-2 |
Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 5.00e-2 | 4.46e-2 |
CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 5.00e-2 | 3.72e-2 |
CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 1.00e-2 | 2.58e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.42e-2 |
Nonalcoholic Liver disease | Nonalcoholic fatty liver disease | ETC | Namjou B | 2019 | 1,106 | 8,571 | 5.00e-2 | 4.03e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 7.13e-4 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 5.00e-2 | 1.81e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-2 | 1.37e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 2.24e-2 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 4.75e-2 |
Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 5.00e-2 | 1.06e-2 |
Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 1.00e-2 | 2.05e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 3.68e-2 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 1.00e-3 | 3.85e-2 |
BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 5.00e-2 | 3.95e-2 |
BMI by age | BMI at 1.5 years old | ETC | Helgeland O | 2019 | NA | 6,800 | 1.00e-3 | 3.55e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 2.09e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.08e-2 |
Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 1.34e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.